Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

CN57 - Association between glycosylated hemoglobin A1C and symptom severity in lung cancer patients with type 2 diabetes undergoing chemotherapy

Date

16 Sep 2021

Session

ePoster Display

Topics

Cancer in Special Situations/ Populations

Tumour Site

Presenters

Maria Lavdaniti

Citation

Annals of Oncology (2021) 32 (suppl_5): S1275-S1281. 10.1016/annonc/annonc697

Authors

M. Lavdaniti1, P. Charitopoulos2, E. Vlachou3, D. Owens3, A. Chatzinikolaou1, K. Kazakos1

Author affiliations

  • 1 Nursing Department, International Hellenic University, 57400 - Thessaloniki/GR
  • 2 Oncology Clinic, Theageneio Hospital, 57400 - Thessaloniki/GR
  • 3 Nursing Department, University of West Attica, 13678 - Athens/GR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract CN57

Background

The number of patients with both cancer and diabetes is rising. Hyperglycaemia is the hallmark sign of diabetes, and cancer patients with pre-existing diabetes have an increased risk for hyperglycaemic events while undergoing cancer treatment. The purpose of this study was to assess a) the symptom severity of lung cancer patients undergoing chemotherapy and b) the influence of HbA1c in symptom severity.

Methods

This was a cross-sectional study conducted in a large oncology hospital in a major city in Northern Greece. It involved a convenience sample consisting of 43 lung cancer patients with type 2 diabetes undergoing cycle 3. Data was collected using the Memorial Symptom of Assessment Scale (MSAS) and a questionnaire to determine the demographic and clinical characteristics.

Results

The majority of patients were men (n = 26, 70.3%) and their mean age was 68.06 ± 1.36 years. The mean of the Global Distress Index was 1.87 ± 0.83, the mean number of symptoms was 22.41 ± 8.03, and the mean scores of the Psychological Symptoms (PSYCH) and Physical symptoms (PHYS) subscales were 1.80 ± 0.66 and 1.94 ± 0.90 respectively. Specifically, the most severe symptoms were pain (2.59 ± 1.22), lack of energy (2.39 ± 1.32), vomiting (2.05 ± 1.43), shortness of breath (2.28 ± 1.39), worrying (2.04 ± 1.55). To investigate the clinical factors (HbA1c, HDL, LDL, etc) that affected the patients’ scores in the MSAS, a series of t tests for independent samples and one-way ANOVAs were implemented. No statistically significant differences were detected in most of the variables. However, patients over 70 years had a higher score in the PSYCH subscale than their younger counterparts (2.08 ± 0.85 vs 1.49 ± 0.81, t(34) = -2.13, p = 0.04, d = 0.71). The Pearson correlation analysis between the HbA1c and total MSAS score showed that there was a negative correlation between them (r = -.841, p < .033) and a negative correlation between the HbA1c and Global Distress Index (r = -.849, p < .036).

Conclusions

This study is the first to evaluate the associations between HbA1c and symptom severity in Greek lung cancer patients with type 2 diabetes receiving chemotherapy. There is a significant need for further research in this field to clarify the relationships uncovered.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.